Date updated:01-05-2007
One hundred years ago, Dr. Alois Alzheimer identified the ailment that bears his name. Scientists are now decoding the disease and testing drugs that could delay and maybe even cure Alzheimer's. Here are the public companies who are beind these drugs designed to treat, delay or prevent Alzheimer's.
According to a recent BusinessWeek article, "there are currently 4.5 million Alzheimer's patients in the U.S., and the direct and indirect costs of caring for them total more than $100 billion a year, making Alzheimer's the third most expensive illness after heart disease and cancer. Yet the federal government budgeted only $645 million for Alzheimer's research for 2007, $7 million less than the prior year. In contrast, $2.6 billion was allocated for research into HIV/AIDS, which afflicts one million Americans."

-
NRMX
N/a - $2.00
- 0.00
- $2.00
The drug Alzhemed is being produced by Neurochem. It prevents the accumulation of amyloid, a toxic protein that destroys brain cells in Alzheimer's victims. It's in Phase 3 late stage testing. The data on Alzhemed have been promising but scant. In a 2002 study it stabilized the disease in nine patients over six months, but the small sample left plenty of specialists skeptical. A clinical trial of the drug will wrap up in January, with results expected in the spring.

-
MYGN
Myriad Genetics - $23.30
- -3.00%
- $24.41
The drug Flurizan is being produced by Myriad Genetics. It inhibits the production of amyloid. It's in Phase 3 of testing with results expected next summer.

-
MEMY
N/a - $0.14
- 0.00
- $0.14
The drug MEM1003 is being produced by Memory Pharmaceuticals. It evens out the irregularities in brain levels of calcium - one of the first manifestations of Alzheimer's. It's in Phase 2 of testing.

-
WYE
Wye - $0.00
- N/A
- $N/A
The drug AAB-001 is being produced by Wyeth and Elan. It's a monoclonal antibody that seeks out and removes amyloid in the brain. It's in Phase 2 of testing.

-
LLY
Lilly Eli Co - $35.36
- +1.09%
- $35.09
The drug LY450139 is being produced by Eli Lilly. It blocks an enzyme that snips off amyloid fragments, thus reducing the production of amyloid. It's in Phase 2 of testing.

-
ELN
Elan Cp Plc Adr - $6.45
- +2.06%
- $6.29
The drug ACC-101 is being produced by Elan and Wyeth. The vaccine prompts the body's immune system to attack and remove amyloid in the brain. It's in Phase 1 (early safety tests)

-
DNA
N/a - $80.43
- 0.00
- $80.43
Nearly 60 drugs designed to modify the disease are in clinical trials. One is from AC Immune of Switzerland who recently struck a deal with biotech power player Genentech Inc. (DNA ). While known for its cancer treatments, Genentech just announced plans to invest $300 million for the rights to AC Immune's drug.
- Top Professional Portfolios
- 1. Navellier & Associ...
- 2. Fidelity Contrafund - ...
- 3. Argus Management
- 4. Charlie Munger
- 5. Calamos Advisors
- show all
- Top Do-It-Yourself Portfolios
- » John Shier
- » Joy
- » tsamanuli Portfolio 1
- » Albo's First Portfolio
- » Fundsonly Portfolio 1
- show all
- Most Viewed Portfolios
- » Warren Buffett
- » George Soros
- » T. Boone Pickens - BP Cap...
- » Carl Icahn
- » Renaissance Technologies
- show all
By Roberto Pedone According to Jim Cramer, investors shouldn’t read too much into Thursday’s market action. He reminded investors that the market has gone up for six...
By Roberto Pedone Posted on Nov. 12, 2009 According to CNBC’s “Fast Money” traders, stocks continued to move higher this week, maintaining their strength off the ...
By Jonas Elmerraji Posted on Nov. 11, 2009 Recently we put our short-squeeze focus on smaller stocks; this week we’re going large-cap. With higher trading volumes, mo...
By Jonas Elmerraji Posted on Nov. 10, 2009 After six straight days of gains, the markets are taking a breather today, which gives us the chance to focus our attention b...
A. yes...he's making his own videos.
A. The only one I own : SLX,
too hard pick a winner out all of them
Here are some of the biggest stocks that made the 52-week high list on Nov. 13, 2009. more
Analyst Upgrades for Nov. 13, 2009. Read more here. more
Here are the 10 stocks in the Dow Jones Industrial Average stocks with the highest yields as of the market close on June 2, 2009. more











Comments not available